Contact Us
Drug Search Results
More Filters [+]

Phenylalanine

Alternative Names: phenylalanine, l-phenylalanine, clinimix, plenamine, clinimix e, travasol, premasol - sulfite-free (amino acid), freamine iii, trophamine, aminosyn ii, hepatamine, aminosyn-pf, procalamine, prosol, clinisol, kabiven, perikabiven
Latest Update: 2024-09-05
Latest Update Note: News Article

Product Description

Mechanisms of Action: Epump

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous,Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Bosnia | Brazil | Chile | China | Croatia | Cyprus | Egypt | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Lebanon | Malaysia | Malta | New Zealand | Norway | Pakistan | Poland | Russia | Serbia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Biomarin
Company Location: NOVATO CA 94949
Company CEO: Jean-Jacques Bienaimé
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Phenylalanine

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Muscle Weakness

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SeND Home

P2

Recruiting

Muscle Weakness

2024-09-30

Recent News Events

Date

Type

Title

09/05/2024

News Article

 Global Phenylethanol Market to reach a valuation of USD 2.9 Billion by 2034, FMI Projection

09/04/2024

News Article

 Jnana Therapeutics Presents New Positive Data from Phase 1/2 Study of JNT-517 in Individuals with Phenylketonuria – Results Support Planned Pivotal Study in Early 2025

09/03/2024

News Article

 IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

09/02/2024

News Article

 Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions